PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Zoellner, A.K.* ; Weiglein, T. ; Hutter, G. ; Zimmermann, Y. ; Cieplik, H.C. ; Hess, G.* ; Dreyling, M.

Temsirolimus acts as additive with bendamustine in aggressive lymphoma.

Ann. Hematol. 95, 403-407 (2015)
Verlagsversion DOI PMC
Open Access Gold
The mammalian target of rapamycin (mTOR) is a protein kinase involved in the phosphatidylinositol 3-kinase (PI3K)/AKT signalling pathway. It plays a pivotal role in the control of cell proliferation, survival, and angiogenesis with multiple and frequent dysregulations of this pathway in human tumors. Temsirolimus is an intravenous drug, specifically inhibiting the mTOR pathway. Bendamustine is well known for its clinical activity in indolent non-Hodgkin-lymphoma (NHL) and has lately shown clinical activity in mantle cell lymphoma (MCL). Here, we present a case report of temsirolimus in combination with bendamustine and rituximab leading to a CR in a pretreated male. In addition, our in vitro data underlines the additive and synergistic efficacy in cell growth reduction of temsirolimus combined with bendamustine in MCL cell lines and in DLBCL cell lines. Furthermore, as an underlying mechanism of this additive, effects on cell cycle inhibition and apoptosis induction could be identified.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
2.634
0.941
7
6
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter Bendamustine ; Dlbcl ; Mcl ; Temsirolimus; Mantle Cell Lymphoma; Non-hodgkin-lymphoma; 1st-line Treatment; Plus Rituximab; Cycle Arrest; Mtor; Combination; Indolent; Trial; Multicenter
Sprache englisch
Veröffentlichungsjahr 2015
HGF-Berichtsjahr 2016
ISSN (print) / ISBN 0939-5555
e-ISSN 1432-0584
Zeitschrift Annals of Hematology
Quellenangaben Band: 95, Heft: 3, Seiten: 403-407 Artikelnummer: , Supplement: ,
Verlag Springer
Verlagsort New York
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Functional Epigenetics (IFE)
POF Topic(s) 30504 - Mechanisms of Genetic and Environmental Influences on Health and Disease
Forschungsfeld(er) Immune Response and Infection
PSP-Element(e) G-501411-001
DOI 10.1007/s00277-015-2570-1
WOS ID WOS:000371605300006
Scopus ID 84949546767
PubMed ID 26658770
Erfassungsdatum 2016-12-31
[➜Korrektur melden]